Lumexa Imaging (NASDAQ:LMRI) Issues FY 2026 Earnings Guidance

Lumexa Imaging (NASDAQ:LMRI) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 0.710-0.770 for the period, compared to the consensus EPS estimate of 0.650. The company issued revenue guidance of $1.0 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Lumexa Imaging Stock Up 1.0%

NASDAQ LMRI opened at $7.78 on Friday. Lumexa Imaging has a twelve month low of $6.45 and a twelve month high of $19.45. The business has a 50-day simple moving average of $9.15.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on LMRI shares. Weiss Ratings started coverage on Lumexa Imaging in a report on Wednesday, May 13th. They issued a “sell (e-)” rating for the company. Raymond James Financial upgraded Lumexa Imaging from an “outperform” rating to a “strong-buy” rating and set a $23.00 price objective for the company in a research note on Monday, February 9th. Finally, Barclays cut their price objective on Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating for the company in a research note on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Insiders Place Their Bets

In other Lumexa Imaging news, Director Brett Brodnax acquired 35,000 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was bought at an average cost of $7.25 per share, for a total transaction of $253,750.00. Following the completion of the transaction, the director owned 62,027 shares of the company’s stock, valued at approximately $449,695.75. The trade was a 129.50% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. purchased a new position in Lumexa Imaging in the fourth quarter worth approximately $37,139,000. Janus Henderson Group PLC purchased a new position in Lumexa Imaging in the fourth quarter worth approximately $36,860,000. ArrowMark Colorado Holdings LLC purchased a new position in Lumexa Imaging in the fourth quarter worth approximately $27,750,000. Invesco Ltd. purchased a new position in Lumexa Imaging in the fourth quarter worth approximately $26,562,000. Finally, Millennium Management LLC purchased a new position in Lumexa Imaging in the fourth quarter worth approximately $23,877,000.

About Lumexa Imaging

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).